VEGF Silencing Inhibits Human Osteosarcoma Angiogenesis and Promotes Cell Apoptosis Via PI3K/AKT Signaling Pathway

Overview

Journal Int J Clin Exp Med

Specialty General Medicine

Date 2015 Nov 10

PMID 26550152

Citations 10

Authors

Jian Zhao

Zi-Ru Zhang

Na Zhao

Bao-An Ma

Qing-Yu Fan

Affiliations

Soon will be listed here.

Abstract

Vascular endothelial growth factor (VEGF) is one of the most potently angiogenic factors which promotes generation of tumor vasculature. VEGF is usually up-regulated in multiple cancers include osteosarcoma and gliomas. To further explore the potential molecular mechanism that inhibits tumor growth induced by interference of VEGF expression, we constructed an Lv-shVEGF vector and assessed the efficiency of VEGF silencing and its influence on U2OS cells. Our data demonstrated that Lv-shVEGF has high inhibition efficiency on VEGF expression, which inhibits proliferation and promotes apoptosis of U2OS cells in vitro. Our results also indicated that inhibition of VEGF expression suppresses osteosarcoma tumor growth in vivo, VEGF inhibition reduces osteosarcoma angiogenesis. We also found that the phosphoinositide 3-kinase (PI3K) and protein kinase B (AKT) activation was considerably reduced after osteosarcoma cells were treated with Lv-shVEGF. Taken together, our data demonstrated that VEGF silencing suppresses cells proliferation, promotes cells apoptosis and reduces osteosarcoma angiogenesis through inactivation of PI3K/AKT signaling pathway.

Citing Articles

MiR-150-5p contributes to unexplained recurrent spontaneous abortion by targeting VEGFA and downregulating the PI3K/AKT/mTOR signaling pathway.

Liao W, Deng X, Chen G, Yang J, Li Y, Li L J Assist Reprod Genet. 2023; 41(1):63-77.

PMID: 37921969 PMC: 10789717. DOI: 10.1007/s10815-023-02959-w.

CRISPR/Cas9: A revolutionary genome editing tool for human cancers treatment.

Akram F, Ul Haq I, Sahreen S, Nasir N, Naseem W, Imitaz M Technol Cancer Res Treat. 2022; 21:15330338221132078.

PMID: 36254536 PMC: 9580090. DOI: 10.1177/15330338221132078.

Polymer-mediated gene therapy: Recent advances and merging of delivery techniques.

Salameh J, Zhou L, Ward S, Santa Chalarca C, Emrick T, Figueiredo M Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019; 12(2):e1598.

PMID: 31793237 PMC: 7676468. DOI: 10.1002/wnan.1598.

AUF1 positively controls angiogenesis through mRNA stabilization-dependent up-regulation of HIF-1α and VEGF-A in human osteosarcoma.

Al-Khalaf H, Aboussekhra A Oncotarget. 2019; 10(47):4868-4879.

PMID: 31448053 PMC: 6690669. DOI: 10.18632/oncotarget.27115.

Identification of mundoserone by zebrafish screening as a natural product with anti-angiogenic activity.

Chen K, Wang C, Fan Y, Gu J, Han Z, Wang Y Exp Ther Med. 2018; 16(6):4562-4568.

PMID: 30542405 PMC: 6257818. DOI: 10.3892/etm.2018.6748.

References

Jin X, Yin J, Kim S, Sohn Y, Beck S, Lim Y . EGFR-AKT-Smad signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven cytokine induction. Cancer Res. 2011; 71(22):7125-34. DOI: 10.1158/0008-5472.CAN-11-1330. View

Wei M, Popescu N, Lerman M, Merrill M, Zimonjic D . Localization of the human vascular endothelial growth factor gene, VEGF, at chromosome 6p12. Hum Genet. 1996; 97(6):794-7. View

Won Y, Lee M, Kim H, Bull D, Kim S . Post-translational regulated and hypoxia-responsible VEGF plasmid for efficient secretion. J Control Release. 2012; 160(3):525-31. PMC: 3372625. DOI: 10.1016/j.jconrel.2012.03.010. View

Valdehita A, Carmena M, Bajo A, Prieto J . RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells. Mol Cell Endocrinol. 2011; 348(1):241-6. DOI: 10.1016/j.mce.2011.08.031. View

Majeti B, Lee J, Simmons B, Shojaei F . VEGF is an important mediator of tumor angiogenesis in malignant lesions in a genetically engineered mouse model of lung adenocarcinoma. BMC Cancer. 2013; 13:213. PMC: 3648493. DOI: 10.1186/1471-2407-13-213. View

Roorda B, Ter Elst A, Scherpen F, Meeuwsen-de Boer T, Kamps W, de Bont E . VEGF-A promotes lymphoma tumour growth by activation of STAT proteins and inhibition of p27(KIP1) via paracrine mechanisms. Eur J Cancer. 2010; 46(5):974-82. DOI: 10.1016/j.ejca.2009.12.027. View

Courties G, Presumey J, Duroux-Richard I, Jorgensen C, Apparailly F . RNA interference-based gene therapy for successful treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2009; 9(5):535-8. DOI: 10.1517/14712590902926089. View

Yamaguchi H, Nojima T, Yagi T, Matsuno T, Sasaki T, Isu K . The alteration in the pattern of pulmonary metastasis with adjuvant chemotherapy in osteosarcoma. Int Orthop. 1988; 12(4):305-8. DOI: 10.1007/BF00317829. View

Leidi M, Mariotti M, Maier J . EDF-1 contributes to the regulation of nitric oxide release in VEGF-treated human endothelial cells. Eur J Cell Biol. 2010; 89(9):654-60. DOI: 10.1016/j.ejcb.2010.05.001. View

10.

Ohba T, Cates J, Cole H, Slosky D, Haro H, Ando T . Autocrine VEGF/VEGFR1 signaling in a subpopulation of cells associates with aggressive osteosarcoma. Mol Cancer Res. 2014; 12(8):1100-11. DOI: 10.1158/1541-7786.MCR-14-0037. View

11.

Fukuhara M, Uchida E, Tajiri T, Aimoto T, Naito Z, Ishiwata T . Re-expression of reduced VEGF activity in liver metastases of experimental pancreatic cancer. J Nippon Med Sch. 2005; 72(3):155-64. DOI: 10.1272/jnms.72.155. View

12.

Wang S, Liu S, Sun H, Huang T, Chan C, Yang C . CCL5/CCR5 axis induces vascular endothelial growth factor-mediated tumor angiogenesis in human osteosarcoma microenvironment. Carcinogenesis. 2014; 36(1):104-14. DOI: 10.1093/carcin/bgu218. View

13.

Ogose A, Yoshizawa T, Kuwano R, Hotta Y, Hotta T, Hatano H . Expression of the coxsackievirus and adenovirus receptor in musculoskeletal tumors and mesenchymal tissues: efficacy of adenoviral gene therapy for osteosarcoma. Cancer Sci. 2003; 94(1):70-5. PMC: 11160042. DOI: 10.1111/j.1349-7006.2003.tb01354.x. View

14.

Zhu K, Engrav L, Armendariz R, Muangman P, Klein M, Carrougher G . Changes in VEGF and nitric oxide after deep dermal injury in the female, red Duroc pig-further similarities between female, Duroc scar and human hypertrophic scar. Burns. 2005; 31(1):5-10. DOI: 10.1016/j.burns.2004.08.010. View

15.

Bielack S, Carrle D, Jost L . Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008; 19 Suppl 2:ii94-6. DOI: 10.1093/annonc/mdn102. View

16.

Weiss K, Cooper G, Jadlowiec J, McGough 3rd R, Huard J . VEGF and BMP expression in mouse osteosarcoma cells. Clin Orthop Relat Res. 2006; 450:111-7. DOI: 10.1097/01.blo.0000229333.98781.56. View

17.

Baker G, Yadav V, Motsch S, Koschmann C, Calinescu A, Mineharu Y . Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy. Neoplasia. 2014; 16(7):543-61. PMC: 4198934. DOI: 10.1016/j.neo.2014.06.003. View

18.

Mosch B, Reissenweber B, Neuber C, Pietzsch J . Eph receptors and ephrin ligands: important players in angiogenesis and tumor angiogenesis. J Oncol. 2010; 2010:135285. PMC: 2836134. DOI: 10.1155/2010/135285. View

19.

Lee L, Sharma S, Morgan B, Allegrini P, Schnell C, Brueggen J . Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients.... Cancer Chemother Pharmacol. 2005; 57(6):761-71. DOI: 10.1007/s00280-005-0120-6. View

20.

Xu M, Xie Y, Sheng W, Miao J, Yang J . Adenovirus-mediated ING4 Gene Transfer in Osteosarcoma Suppresses Tumor Growth via Induction of Apoptosis and Inhibition of Tumor Angiogenesis. Technol Cancer Res Treat. 2014; 14(4):369-78. DOI: 10.1177/1533034614500424. View